Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Dr Golant on Atopic Dermatitis (October 2026)

Dr Golant on Atopic Dermatitis (October 2026)

Dr Bhutani-Jacques on Psoriasis (October 2026)

Dr Bhutani-Jacques on Psoriasis (October 2026)

How do you determine the role of steroidal and nonsteroidal topical therapies within a longer-term treatment plan?

Oct 20, 2026Atopic Dermatitis

How do you determine the role of steroidal and nonsteroidal topical therapies within a longer-term treatment plan?

-

What does moderate AD look like in real-world practice, and what can make its severity easy to underestimate?

Oct 20, 2026Atopic Dermatitis

What does moderate AD look like in real-world practice, and what can make its severity easy to underestimate?

-

Where does ruxolitinib cream fit into your current approach to topical treatment for AD?

Oct 20, 2026Atopic Dermatitis

Where does ruxolitinib cream fit into your current approach to topical treatment for AD?

-

Where does ruxolitinib cream fit for patients who have relied on repeated courses of topical corticosteroids to manage their AD?

Oct 20, 2026Atopic Dermatitis

Where does ruxolitinib cream fit for patients who have relied on repeated courses of topical corticosteroids to manage their AD?

-

What have you learned about setting expectations for ruxolitinib cream that helps patients use it appropriately in real-world practice?

Oct 20, 2026Atopic Dermatitis

What have you learned about setting expectations for ruxolitinib cream that helps patients use it appropriately in real-world practice?

-

How does targeting JAK-STAT signaling in the skin translate into the clinical effects seen with ruxolitinib cream in AD?

Oct 20, 2026Atopic Dermatitis

How does targeting JAK-STAT signaling in the skin translate into the clinical effects seen with ruxolitinib cream in AD?

-

When clinicians and patients have different priorities around how a treatment is administered, how do you navigate that conversation?

Oct 2, 2026Psoriasis

When clinicians and patients have different priorities around how a treatment is administered, how do you navigate that conversation?

-

When patients are doing well on biologic therapy, how do you maintain meaningful clinical engagement without creating unnecessary treatment burden?

Oct 2, 2026Psoriasis

When patients are doing well on biologic therapy, how do you maintain meaningful clinical engagement without creating unnecessary treatment burden?

-

What assumptions do clinicians sometimes make about patients' preference for self-administration that don't necessarily hold true in practice?

Oct 2, 2026Psoriasis

What assumptions do clinicians sometimes make about patients' preference for self-administration that don't necessarily hold true in practice?

-

What does HCP administration allow you to know about a patient's treatment that can be harder to assess with a self-administered biologic?

Oct 2, 2026Psoriasis

What does HCP administration allow you to know about a patient's treatment that can be harder to assess with a self-administered biologic?

-

What have you learned from patients who seemed well suited to self-administration initially but encountered challenges once treatment was underway?

Oct 2, 2026Psoriasis

What have you learned from patients who seemed well suited to self-administration initially but encountered challenges once treatment was underway?

-

When you're considering tildrakizumab for a patient with psoriasis, how does its HCP-administered model factor into your treatment decision?

Oct 2, 2026Psoriasis

When you're considering tildrakizumab for a patient with psoriasis, how does its HCP-administered model factor into your treatment decision?

-

What tends to cause clinicians or patients to fall into a reactive pattern of treating AKs as they appear rather than developing a longer-term management strategy?

Oct 1, 2026Actinic Keratosis

What tends to cause clinicians or patients to fall into a reactive pattern of treating AKs as they appear rather than developing a longer-term management strategy?

-

What do you try to understand when a patient who would benefit from field therapy is reluctant to move forward with treatment?

Oct 1, 2026Actinic Keratosis

What do you try to understand when a patient who would benefit from field therapy is reluctant to move forward with treatment?

-

What should clinicians know about cash-pay or network pharmacy pathways for Medicare patients who have been prescribed tirbanibulin?

Oct 1, 2026Actinic Keratosis

What should clinicians know about cash-pay or network pharmacy pathways for Medicare patients who have been prescribed tirbanibulin?

-

Can you describe a patient who was reluctant to undergo field therapy again after a difficult previous experience and how tirbanibulin affected your treatment approach?

Oct 1, 2026Actinic Keratosis

Can you describe a patient who was reluctant to undergo field therapy again after a difficult previous experience and how tirbanibulin affected your treatment approach?

-

Have younger patients presented different priorities or concerns around field therapy that have influenced your decision to use tirbanibulin?

Oct 1, 2026Actinic Keratosis

Have younger patients presented different priorities or concerns around field therapy that have influenced your decision to use tirbanibulin?

-

What has led you to consider tirbanibulin earlier in AK management rather than reserving field therapy for patients with more extensive disease?

Oct 1, 2026Actinic Keratosis

What has led you to consider tirbanibulin earlier in AK management rather than reserving field therapy for patients with more extensive disease?

-

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

Sep 4, 2026Psoriasis

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

-

What have you learned from patients who have remained on tildrakizumab long term?

Sep 4, 2026Psoriasis

What have you learned from patients who have remained on tildrakizumab long term?

-

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

Sep 4, 2026Psoriasis

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

-

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

Sep 4, 2026Psoriasis

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

-

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

Sep 4, 2026Psoriasis

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

-

Are there patients you consider medically complex who might not fit the traditional definition?

Sep 4, 2026Psoriasis

Are there patients you consider medically complex who might not fit the traditional definition?

-

Dermbits - Watch short videos of KOLs answering your questions